Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CDC7 | O00311 | 1/20 | 0.54 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8114168 | 0.98 | ALDH1A1 (0.71) | ALDH1A1CYP1A2HPGDHSD17B10LMNA | |
| SCHEMBL23372773 | 0.88 | ALDH1A1 (0.58) | ALDH1A1CYP1A2HPGDHSD17B10LMNA | |
| SCHEMBL8484927 | 0.86 | ALDH1A1 (0.56) | ALDH1A1CYP1A2HPGDHSD17B10LMNA | |
| SCHEMBL3921966 | 0.84 | ALDH1A1 (0.71) | ALDH1A1CYP1A2HPGDHSD17B10LMNA | |
| SCHEMBL3119761 | 0.84 | ALDH1A1 (1.00) | ALDH1A1CYP1A2HPGDHSD17B10LMNA | |
| SCHEMBL10532170 | 0.83 | ALDH1A1 (0.57) | ALDH1A1CYP1A2HPGDHSD17B10MAPT | |
| SCHEMBL1552396 | 0.83 | ALDH1A1 (0.69) | ALDH1A1CYP1A2HPGDHSD17B10LMNA | |
| SCHEMBL23703077 | 0.83 | ALDH1A1 (0.69) | ALDH1A1CYP1A2HPGDHSD17B10LMNA | |
| SCHEMBL859765 | 0.83 | ALDH1A1 (0.69) | ALDH1A1CYP1A2HPGDHSD17B10LMNA | |
| SCHEMBL276275 | 0.81 | ALDH1A1 (0.62) | ALDH1A1CYP1A2HPGDMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 395 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120136809-A | Febuxostat Process for the preparation of intermediates | 无棣锐新医药化工有限公司 | 2025-06-13 | — | — | CN | claimed |
| CN-102942565-A | 3,4-dichloro isothiazole derivatives, their preparation method and application | JIANGXI TIANREN ECOLOGY CO LTD | 2013-02-27 | — | — | CN | claimed |
| CN-102079732-A | Method for synthesizing 2-amino-4-methylthiazole-5-carboxylate and derivatives thereof | UNIV XI AN JIAOTONG | 2011-06-01 | — | — | CN | claimed |
| US-12545654-B2 | MYC inhibitors and uses thereof | STEMSYNERGY THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12479809-B2 | Hydrazone amide derivative and application thereof in preparation of medicaments for preventing and treating alopecia | SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2025-11-25 | — | — | US | disclosed |
| CN-120136809-A | Febuxostat Process for the preparation of intermediates | 无棣锐新医药化工有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120136809-A | Febuxostat Process for the preparation of intermediates | 无棣锐新医药化工有限公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025056690-A1 | PARP1- AND IMMUNE-CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCER PATIENTS OVEREXPRESSING UBQLN1 AND/OR UBQLN4 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-03-20 | — | — | WO | disclosed |
| US-12252459-B2 | Hydrazone amide derivatives and use thereof in preparation of anti-osteoporosis drugs | SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2025-03-18 | — | — | US | disclosed |
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2025-03-13 | — | — | US | disclosed |
| CN-119421877-A | Substituted heterocyclic compounds as HSET inhibitors | 默克专利股份公司 | 2025-02-11 | — | — | CN | disclosed |
| US-4424155-A | 3-AMINO-1,2,4-OXADIAZOL-5-YL DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 1984-01-03 | — | — | US | disclosed |
| US-4325870-A | DIAZOTIZATION, AMINATION | CASSELLA AKTIENGESELLSCHAFT (DE) | 1982-04-20 | — | — | US | disclosed |
| US-4154577-A | Uniformly disperse dyed water-swellable cellulosic fibers | BASF AKTIENGESELLSCHAFT (DE) | 1979-05-15 | — | — | US | disclosed |
| US-4128545-A | DISPERSE, POLYESTER | BASF AKTIENGESELLSCHAFT (DE) | 1978-12-05 | — | — | US | disclosed |
| US-4051099-A | ISOINDOLES | CIBA-GEIGY CORPORATION (US) | 1977-09-27 | — | — | US | disclosed |
| US-4042578-A | POLYESTERS | BADISCHE ANILIN- & SODA-FABRIK AKTIENGESELLSCHAFT (DT) | 1977-08-16 | — | — | US | disclosed |
| US-4016152-A | SUITABLE FOR DYEING POLYESTERS | BASF AKTIENGESELLSCHAFT (DT) | 1977-04-05 | — | — | US | disclosed |
| US-3974123-A | Dyes for thermoplastics | BASF AKTIENGESELLSCHAFT (DT) | 1976-08-10 | — | — | US | disclosed |
| US-3950321-A | POLYESTERS | BASF AKTIENGESELLSCHAFT (DT) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | VHL, CDKN1A, CCNI | ALDH1A1 1680/4885CYP1A2 2245/4885HPGD 204/4885 |
| US-12479809-B2 | Hydrazone amide derivative and application thereof in preparation of medicaments for preventing and treating alopecia | FH, HDGF, HRH4 | ALDH1A1 652/4885CYP1A2 299/4885HPGD 33/4885 |
| US-12252459-B2 | Hydrazone amide derivatives and use thereof in preparation of anti-osteoporosis drugs | SOST, HDAC5, PTH1R | ALDH1A1 644/4885CYP1A2 265/4885HPGD 34/4885 |
| US-12545654-B2 | MYC inhibitors and uses thereof | MYC, MYCBP, NR2E1 | ALDH1A1 4317/4885CYP1A2 3304/4885HPGD 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.